Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer | Breast Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Gabai-Kapara  E, Lahad  A, Kaufman  B,  et al.  Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.   Proc Natl Acad Sci U S A. 2014;111(39):14205-14210. doi:10.1073/pnas.1415979111PubMedGoogle ScholarCrossref
2.
Marchetti  C, De Felice  F, Palaia  I,  et al.  Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.   BMC Womens Health. 2014;14(1):150. doi:10.1186/s12905-014-0150-5PubMedGoogle ScholarCrossref
3.
Heemskerk-Gerritsen  BAM, Jager  A, Koppert  LB,  et al.  Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.   Breast Cancer Res Treat. 2019;177(3):723-733. doi:10.1007/s10549-019-05345-2PubMedGoogle ScholarCrossref
4.
Metcalfe  K, Eisen  A, Senter  L,  et al; Hereditary Breast Cancer Clinical Study Group.  International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.   Br J Cancer. 2019;121(1):15-21. doi:10.1038/s41416-019-0446-1PubMedGoogle ScholarCrossref
5.
Daly  MB, Pilarski  R, Yurgelun  MB,  et al; National Comprehensive Cancer Network.  NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020.   J Natl Compr Canc Netw. 2020;18(4):380-391. doi:10.6004/jnccn.2020.0017PubMedGoogle ScholarCrossref
6.
Domchek  S, Robson  M.  Broadening criteria for BRCA1/2 evaluation: placing the USPSTF recommendation in context.   JAMA. 2019;322(7):619-621. doi:10.1001/jama.2019.9688PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    July 9, 2020

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer

    Author Affiliations
    • 1Breast Surgery Unit, Department of Surgery, Shaare Zedek Medical Center, Jerusalem, Israel
    • 2Department of Obstetrics & Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
    • 3Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel
    • 4Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
    • 5Breast Imaging Unit, Department of Imaging, Shaare Zedek Medical Center, Jerusalem, Israel
    • 6Departments of Radiation Oncology and Medicine, University of Colorado, Anschutz Medical Campus, Aurora
    JAMA Oncol. 2020;6(9):1460-1463. doi:10.1001/jamaoncol.2020.2059
    ×